alisertib + rituximab + vincristine

The drug is a **combination therapy** comprising **alisertib**, **rituximab**, and **vincristine** studied primarily for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL), including diffuse large B-cell lymphoma (DLBCL)[1][4][6]. **Alisertib** is a selective small molecule inhibitor of **Aurora A kinase**, a serine/threonine kinase involved in mitotic spindle formation and cell division. **Rituximab** is a monoclonal antibody targeting **CD20** found on B-cells, inducing cell death via immune-mediated mechanisms. **Vincristine** is a chemotherapeutic agent that disrupts microtubule formation, inhibiting mitosis. Preclinical results showed **synergy** between alisertib and vincristine for cell cycle disruption and apoptosis, which was further enhanced by adding rituximab[6]. This combination is intended to maximize anti-tumor efficacy by targeting mitotic and apoptotic pathways in aggressive B-cell lymphomas. The primary clinical indication studied is relapsed/refractory aggressive B-cell NHL, especially non-GCB DLBCL[1][4][6].